Rhythm Pharmaceuticals Reports Strong IMCIVREE Launch and Pipeline Progress — Rhythm Pharmaceuticals, Inc.

Event summary

IMCIVREE® (setmelanotide) for acquired hypothalamic obesity (HO) saw over 400 patient start forms since FDA approval on March 19, 2026.
Second quarter 2026 net product revenue from global sales of IMCIVREE reached $71.3 million, a 19% sequential increase.
Weekly injectable MC4R agonist RM-718 achieved mean BMI reduction of 11.6% in patients with acquired HO after 16 weeks of treatment.
Phase 3 TRANSCEND Trial Results in Acquired HO published in the New England Journal of Medicine on July 8, 2026.

The big picture

Rhythm Pharmaceuticals is making significant strides in both commercial execution and clinical development, particularly with its lead asset IMCIVREE. The strong launch of IMCIVREE for acquired hypothalamic obesity (HO) underscores the unmet need in this rare disease space. The company's pipeline progress, including positive results for RM-718 and setmelanotide in Prader-Willi syndrome, positions it well to expand its market reach. However, sustaining this momentum will depend on successful regulatory approvals and continued strong commercial performance.

What we're watching

Commercial Execution: The pace at which Rhythm Pharmaceuticals can sustain the strong U.S. launch of IMCIVREE for acquired HO and expand into Japan and Europe.
Pipeline Progress: Whether the positive Phase 2 results for setmelanotide in Prader-Willi syndrome (PWS) and RM-718 in acquired HO will translate into successful Phase 3 trials.
Regulatory Milestones: The timing of Japan's Ministry of Health, Labour and Welfare (MHLW) decision on IMCIVREE launch and the initiation of a pivotal Phase 3 trial evaluating bivamelagon in acquired HO by year-end 2026.